J&J, erring on caution, tests new 2-dose regimen for COVID-19 vaccine

Johnson & Johnson is confident that it has a one-dose knockout vaccine that can protect against COVID-19, but it’s now starting a late-stage two-dose test just in case.

The Big Pharma’s vaccine, Ad26.COV2.S (now also known as JNJ-78436735), is currently in a major 60,000-subject phase 3 known as ENSEMBLE assessing whether it can stop COVID-19 infections with a single shot.